Table 1.
ATC classification of gonadorelina registered forms which is used for treatment od advent tumors prostate in Republic of Serbia
| Mark | Clasification | DDD (1000/day)23 | Method of administration/application |
|---|---|---|---|
| L | Antineoplastic and immunomodulators | ||
| 02 | Endocrinological therapy | ||
| A | Hormones and related drugs | ||
| E | Gonadorelin-releasing hormone analogues | ||
| 02 | Leuprorelin16,17 | 60 mcg | intramuscular / subcutaneous |
| 03 | Goserelin18,19 | 0,129 mg | subcutaneous |
| 04 | Triptorelin20,21,22 | 0,134 mg | intramuscular (i.m.) |
Figure 1.
Consumption of gonadorelin analogues by type of drug by years.
Figure 2.
Consumption of gonadorelin analogues by formulation by year
Table 2.
Overview of the five-year consumption of all LHRH agonists used, depending on the dose and formulation of the drug
| International Nonproprietary Name – INN formulation | Proprietary name | Dosage | Pharmaceutical formulation | Consumption (DDD/1000/day) |
|---|---|---|---|---|
| leuprorelin (monthly) | Lupron® 3.75 mg/ml | 3.75 mg/ml | Powder and solvent for suspension for injection in a pre-filled syringe | 0,004357974 |
| leuprorelin (q3-month) | Lupron® 11.25 mg/ml | 11.25 mg/ml | Powder and solvent for suspension for injection in a pre-filled syringe | 0,001289482 |
| leuprorelin (q3-month) | Lutrate depo® 22.5mg | 22.5 mg | Powder and solvent for prolonged-release suspension for injection | 0,019165 |
| goserelin (monthly) | Zoladex® | 3.6 mg | Implant, in pre-filled syringe | 0,019552701 |
| goserelin (q3-month) | Zoladex® LA | 10.8 mg | Implant, in pre-filled syringe | 0,002876386 |
| triptorelin (monthly) | Diphereline® 3.75 mg/2 ml | 3.75 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,176707295 |
| triptorelin (q3-month) | Diphereline® 11.25 mg/2 ml | 11.25 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,021587071 |
| triptorelin (q6-month) | Diphereline® 22.5 mg/2 mL | 22.5 mg/2 ml | Powder and solvent for prolonged-release suspension for injection | 0,00096538 |
Table 3.
Comparative data on the consumption of gonadorelin analogues at the Clinic of Urology of the University Medical Center Kragujevac, as well as in Serbia, Croatia and Italy by years.
| International Nonproprietary Name/region | Consumption of LHRH agonists in DDD / 1000 / day ** per year | ||||
|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | |
| Clinic of Urology, UCC Kragujevac | |||||
| Leuprorelin | 0,0020 | 0,0022 | 0,0005 | 0,0017 | 0,0184 |
| Goserelin | 0,0028 | 0,0037 | 0,0054 | 0,0070 | 0,0035 |
| Triptorelin | 0,0353 | 0,0316 | 0,0441 | 0,0489 | 0,0394 |
| Total | 0,0402 | 0,0375 | 0,0500 | 0,0576 | 0,0613 |
| Serbia12 | |||||
| Leuprorelin | 0,0563 | 0,0720 | 0,0014 | 0,0055 | N/A * |
| Goserelin | 0,1035 | 0,0841 | 0,0832 | 0,0821 | N/A |
| Triptorelin | 0,1927 | 0,2076 | 0,2706 | 0,2817 | N/A |
| Total | 0,3526 | 0,3637 | 0,3552 | 0,3694 | N/A |
| Croatia13 | |||||
| Leuprorelin | 0,5700 | 0,5800 | 0,5900 | 0,7800 | N/A |
| Goserelin | 0,0900 | 0,1100 | 0,1300 | 0,1900 | N/A |
| Triptorelin | 0,0300 | 0,0300 | 0,2300 | 0,2300 | N/A |
| Total | 0,6900 | 0,7200 | 0,9500 | 1,2000 | N/A |
| Italy14 | |||||
| Leuprorelin | N/A | 0,2000 | 0,2000 | 0,2000 | N/A |
| Goserelin | N/A | 0,0000 | 0,0000 | 0,0000 | N/A |
| Triptorelin | N/A | 0,7000 | 0,8000 | 0,8000 | N/A |
| Total | N/A | 0,9000 | 1,0000 | 1,0000 | N/A |